BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
Volume 0.00M
Average 0.01M
BCT.TO Inventory
Raw materials, work in progress, and finished goods held for sale.
BriaCell Therapeutics Corp.TSX: BCT.TO
Inventory · Q3 FY2026 · quarter ended Apr 2026
Inventory remains negative
Q3 FY2026 inventory was $0, compared with $0 a year earlier.
Context
- Inventory amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Inventory increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Inventory history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 0 | — |
| FY2024 | 2024-07-31 | 0 | — |
| FY2023 | 2023-07-31 | 0 | — |
| FY2022 | 2022-07-31 | 0 | — |
| FY2021 | 2021-07-31 | 0 | — |
Inventory vs competitors
How BCT.TO compares with its peers on the latest reported figures
No competitor Inventory figures are available to compare.
Balance Sheet
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 57.27M | 41.04M | 21.25M | 862.09K | 10.53M |
| Short-term Investments | 0 | 0 | 0 | 0 | 7.4M |
| Net Receivables | 12.57K | 24.1K | 717.74K | 1.37M | 566.73K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 57.8M | 42.35M | 26.95M | 3.65M | 19.99M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 388.18K | 297.84K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 245.61K | 230.34K | 215.07K | 199.8K | 185.16K |
| Long-term Investments | 0 | 0 | 0 | 418.49K | 526.07K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 1.21M | 719.97K |
| Total Non-current Assets | 245.61K | 230.34K | 215.07K | 2.22M | 1.73M |
| Total Assets | 58.04M | 42.58M | 27.16M | 5.87M | 21.72M |
| Account Payables | 214.12K | 463.28K | 1.12M | 7.17M | 3.29M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 696.66K |
| Total Current Liabilities | 556.8K | 941.09K | 1.8M | 7.46M | 3.99M |
| Long-term Debt | 25.99K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 29.79M | 31.31M | 29.14M | 1.1M | 338.83K |
| Total Non-current Liabilities | 29.82M | 31.31M | 29.14M | 1.1M | 338.83K |
| Total Liabilities | 30.37M | 32.25M | 30.94M | 8.56M | 4.33M |
| Common Stock | 54.77M | 65.59M | 69.59M | 72.17M | 102.09M |
| Retained Earnings | (29.14M) | (60.35M) | (80.65M) | (85.44M) | (112.14M) |
| Accumulated OCI | (138.68K) | (138.68K) | (138.68K) | (138.68K) | 27.99M |
| Other Stockholders Equity | 0 | 0 | 0 | 11.03M | 0 |
| Minority Interest | 0 | 0 | 0 | (302.52K) | (548.67K) |
| Total Equity | 27.67M | 10.33M | (3.78M) | (2.68M) | 17.39M |
| Total Debt | 25.99K | 0 | 0 | 0 | 0 |
| Net Debt | (57.24M) | (41.04M) | (21.25M) | (862.09K) | (10.53M) |
BriaCell Therapeutics Corp.
TSX:BCT.TO
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.